Health Trials

RB1-Negative

1

Review clinical trials related to RB1-Negative. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy

To learn if the study drug REC-617 can help to control LMS. The safety of REC-617 will also be studied.

Participants needed: 15
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Jun 24, 2026Locations: 1
Eligibility criteria

Histologically confirmed leiomyosarcoma (any site of origin). [+17]

Participants who are receiving any other investigational agents or have received... [+12]

Read more